In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synosia Therapeutics Inc.

Division of Acorda Therapeutics Inc.
www.synosia.com

Latest From Synosia Therapeutics Inc.

Biotie Gears Up For New Pivotal Trial Of Tozadenant In Parkinson’s

With the goal of introducing the first adenosine A2a antagonist for Parkinson’s disease in North America and Europe, Biotie plans to start a Phase III study of tozadenant in almost 900 Parkinson’s patients this summer.

BioPharmaceutical Clinical Trials

Biotie Gears Up For New Pivotal Trial Of Tozadenant In Parkinson’s

With the goal of introducing the first adenosine A2a antagonist for Parkinson’s disease in North America and Europe, Biotie plans to start a Phase III study of tozadenant in almost 900 Parkinson’s patients this summer.

Clinical Trials

Versant Ventures Looks To Canada, Europe For New Deals

Hoping to boost its international dealmaking, the California venture firm is setting up shop in Vancouver, BC, and expanding in Switzerland, to gain access to emerging projects that haven’t been “picked over.”

BioPharmaceutical United States

Biotie Therapies’ Options Expand On Nalmefene And Tozadenant Progress

Finland's only publicly listed biotech, Biotie Therapies, is reviewing its licensing and M&A options in niche CNS areas as product milestone payments and equity investments expand its cash runway.

BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Synosis Therapeutics Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Acorda Therapeutics Inc.
  • Senior Management
  • Ian Massey, Pres. & CEO
    Stephen I Bandak, MD, CMO
    Zachary McNealy, VP, Fin.
  • Contact Info
  • Synosia Therapeutics Inc.
    Phone: (41) 61 206 9202
    Aeschenvorstadt 36
    Basel , CH-4051
    Switzerland
UsernamePublicRestriction

Register